Xortx Therapeutics Shares Rise After Company Reports Potential Partner Interest for Gout Program
MT Newswires Live
8 hours ago
Xortx Therapeutics (XRTX) shares rose 22% in after-hours trading after the company said it has received inquiries from potential commercialization partners for its XRx-026 gout program, though it has not entered into any agreements.
The company said Thursday its planned Clinical Trial Application submission to Health Canada would support a two-part clinical study, XRX-OXY-102, evaluating Xorlo, its proprietary oxypurinol formulation, for the treatment of gout.
Xortx said that conducting the first part of the study in Canada could accelerate key clinical data needed for a planned new drug application with the US Food and Drug Administration.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.